US EditionEli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
UNITED STATES, AUG 7 – Eli Lilly's orforglipron achieved 12.4% average weight loss in a late-stage trial, below analysts' 13-15% expectations, causing shares to drop 14%, its largest single-day loss since 2000.
6 Articles
6 Articles
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
It’s been a week of wins for Eli Lilly’s weight-loss drugs. In the company’s second quarter earnings report on Thursday, it reported that sales of Mounjaro, its type-2 diabetes medication often used for weight loss, reached nearly $5.2 billion in revenue, up 68% from the same quarter last year and exceeding analyst estimates of $4.7 billion. Similarly, its weight-loss medication Zepbound reached $3.4 billion in sales, up 172% year-over-year and …
Eli Lilly shares plunge after disappointing dataA disappointing auction of 30-year US Treasury securities came close to ruining the last good mood on Wall Street on Thursday evening, as the Nasdaq index b
Eli Lilly obtained a net profit of $5.6 billion (€4,873 million) in the second quarter of 2025, representing an increase of 91% compared to the result scored a year earlier by the US pharmaceutical company, whose shares plummeted on Wall Street this Thursday after presenting the results of a clinical trial of his obesity pill.
The laboratory's actions plummet after the results of its anti-obesity pill MADRID, 7 (EUROPA PRESS) Eli Lilly obtained a net profit of 5.6 billion dollars (4,873 million euros) in the second quarter of 2025, representing an increase of 91% compared to the result scored a year [...] The entry Eli Lilly wins a 91% more in the second trimester and raises annual forecasts aparece primero en Forbes España.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
